Major challenges and potential microenvironment-targeted therapies in glioblastoma

Ali S. Arbab, Mohammad H. Rashid, Kartik Angara, Thaiz F. Borin, Ping Chang Lin, Meenu Jain, Bhagelu R. Achyut

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Glioblastoma (GBM) is considered one of the most malignant, genetically heterogeneous, and therapy-resistant solid tumor. Therapeutic options are limited in GBM and involve surgical resection followed by chemotherapy and/or radiotherapy. Adjuvant therapies, including antiangiogenic treatments (AATs) targeting the VEGF–VEGFR pathway, have witnessed enhanced infiltration of bone marrow-derived myeloid cells, causing therapy resistance and tumor relapse in clinics and in preclinical models of GBM. This review article is focused on gathering previous clinical and preclinical reports featuring major challenges and lessons in GBM. Potential combination therapies targeting the tumor microenvironment (TME) to overcome the myeloid cell-mediated resistance problem in GBM are discussed. Future directions are focused on the use of TME-directed therapies in combination with standard therapy in clinical trials, and the exploration of novel therapies and GBM models for preclinical studies. We believe this review will guide the future of GBM research and therapy.

Original languageEnglish (US)
Article number2732
JournalInternational journal of molecular sciences
Volume18
Issue number12
DOIs
StatePublished - Dec 16 2017

Fingerprint

Glioblastoma
Tumors
therapy
tumors
Chemotherapy
Radiotherapy
Tumor Microenvironment
Therapeutics
Infiltration
Myeloid Cells
Bone
bone marrow
infiltration
chemotherapy
cells
Cell- and Tissue-Based Therapy
radiation therapy
Neoplasms
Bone Marrow
Clinical Trials

Keywords

  • Antiangiogenic therapy
  • Bone marrow-derived cells
  • Glioblastoma
  • Myeloid cells
  • Neovascularization
  • Resistance
  • Tumor microenvironment

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Major challenges and potential microenvironment-targeted therapies in glioblastoma. / Arbab, Ali S.; Rashid, Mohammad H.; Angara, Kartik; Borin, Thaiz F.; Lin, Ping Chang; Jain, Meenu; Achyut, Bhagelu R.

In: International journal of molecular sciences, Vol. 18, No. 12, 2732, 16.12.2017.

Research output: Contribution to journalReview article

Arbab, Ali S. ; Rashid, Mohammad H. ; Angara, Kartik ; Borin, Thaiz F. ; Lin, Ping Chang ; Jain, Meenu ; Achyut, Bhagelu R. / Major challenges and potential microenvironment-targeted therapies in glioblastoma. In: International journal of molecular sciences. 2017 ; Vol. 18, No. 12.
@article{c6acc59098f848c9b3c58269193527f0,
title = "Major challenges and potential microenvironment-targeted therapies in glioblastoma",
abstract = "Glioblastoma (GBM) is considered one of the most malignant, genetically heterogeneous, and therapy-resistant solid tumor. Therapeutic options are limited in GBM and involve surgical resection followed by chemotherapy and/or radiotherapy. Adjuvant therapies, including antiangiogenic treatments (AATs) targeting the VEGF–VEGFR pathway, have witnessed enhanced infiltration of bone marrow-derived myeloid cells, causing therapy resistance and tumor relapse in clinics and in preclinical models of GBM. This review article is focused on gathering previous clinical and preclinical reports featuring major challenges and lessons in GBM. Potential combination therapies targeting the tumor microenvironment (TME) to overcome the myeloid cell-mediated resistance problem in GBM are discussed. Future directions are focused on the use of TME-directed therapies in combination with standard therapy in clinical trials, and the exploration of novel therapies and GBM models for preclinical studies. We believe this review will guide the future of GBM research and therapy.",
keywords = "Antiangiogenic therapy, Bone marrow-derived cells, Glioblastoma, Myeloid cells, Neovascularization, Resistance, Tumor microenvironment",
author = "Arbab, {Ali S.} and Rashid, {Mohammad H.} and Kartik Angara and Borin, {Thaiz F.} and Lin, {Ping Chang} and Meenu Jain and Achyut, {Bhagelu R.}",
year = "2017",
month = "12",
day = "16",
doi = "10.3390/ijms18122732",
language = "English (US)",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Major challenges and potential microenvironment-targeted therapies in glioblastoma

AU - Arbab, Ali S.

AU - Rashid, Mohammad H.

AU - Angara, Kartik

AU - Borin, Thaiz F.

AU - Lin, Ping Chang

AU - Jain, Meenu

AU - Achyut, Bhagelu R.

PY - 2017/12/16

Y1 - 2017/12/16

N2 - Glioblastoma (GBM) is considered one of the most malignant, genetically heterogeneous, and therapy-resistant solid tumor. Therapeutic options are limited in GBM and involve surgical resection followed by chemotherapy and/or radiotherapy. Adjuvant therapies, including antiangiogenic treatments (AATs) targeting the VEGF–VEGFR pathway, have witnessed enhanced infiltration of bone marrow-derived myeloid cells, causing therapy resistance and tumor relapse in clinics and in preclinical models of GBM. This review article is focused on gathering previous clinical and preclinical reports featuring major challenges and lessons in GBM. Potential combination therapies targeting the tumor microenvironment (TME) to overcome the myeloid cell-mediated resistance problem in GBM are discussed. Future directions are focused on the use of TME-directed therapies in combination with standard therapy in clinical trials, and the exploration of novel therapies and GBM models for preclinical studies. We believe this review will guide the future of GBM research and therapy.

AB - Glioblastoma (GBM) is considered one of the most malignant, genetically heterogeneous, and therapy-resistant solid tumor. Therapeutic options are limited in GBM and involve surgical resection followed by chemotherapy and/or radiotherapy. Adjuvant therapies, including antiangiogenic treatments (AATs) targeting the VEGF–VEGFR pathway, have witnessed enhanced infiltration of bone marrow-derived myeloid cells, causing therapy resistance and tumor relapse in clinics and in preclinical models of GBM. This review article is focused on gathering previous clinical and preclinical reports featuring major challenges and lessons in GBM. Potential combination therapies targeting the tumor microenvironment (TME) to overcome the myeloid cell-mediated resistance problem in GBM are discussed. Future directions are focused on the use of TME-directed therapies in combination with standard therapy in clinical trials, and the exploration of novel therapies and GBM models for preclinical studies. We believe this review will guide the future of GBM research and therapy.

KW - Antiangiogenic therapy

KW - Bone marrow-derived cells

KW - Glioblastoma

KW - Myeloid cells

KW - Neovascularization

KW - Resistance

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85038413424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038413424&partnerID=8YFLogxK

U2 - 10.3390/ijms18122732

DO - 10.3390/ijms18122732

M3 - Review article

C2 - 29258180

AN - SCOPUS:85038413424

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

M1 - 2732

ER -